Cipla Claims Success With Advair Trial
Indian Firm Has Warned FDA Review Could Last Two Years
Executive Summary
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.